413 related articles for article (PubMed ID: 26400304)
1. Expression of c-myc and mutation of the KRAS gene in patients with ovarian mucinous tumors.
Li XS; Sun J; He XL
Genet Mol Res; 2015 Sep; 14(3):10752-9. PubMed ID: 26400304
[TBL] [Abstract][Full Text] [Related]
2. Expression and mutational analysis of c-kit in ovarian surface epithelial tumors.
Kim DJ; Lee MH; Park TI; Bae HI
J Korean Med Sci; 2006 Feb; 21(1):81-5. PubMed ID: 16479070
[TBL] [Abstract][Full Text] [Related]
3. K-ras mutations in mucinous ovarian tumors: a clinicopathologic and molecular study of 95 cases.
Cuatrecasas M; Villanueva A; Matias-Guiu X; Prat J
Cancer; 1997 Apr; 79(8):1581-6. PubMed ID: 9118042
[TBL] [Abstract][Full Text] [Related]
4. Heterogeneous genetic alterations in ovarian mucinous tumors: application and usefulness of laser capture microdissection.
Takeshima Y; Amatya VJ; Daimaru Y; Nakayori F; Nakano T; Inai K
Hum Pathol; 2001 Nov; 32(11):1203-8. PubMed ID: 11727259
[TBL] [Abstract][Full Text] [Related]
5. Two types of primary mucinous ovarian tumors can be distinguished based on their origin.
Simons M; Simmer F; Bulten J; Ligtenberg MJ; Hollema H; van Vliet S; de Voer RM; Kamping EJ; van Essen DF; Ylstra B; Schwartz LE; Wang Y; Massuger LF; Nagtegaal ID; Kurman RJ
Mod Pathol; 2020 Apr; 33(4):722-733. PubMed ID: 31695154
[TBL] [Abstract][Full Text] [Related]
6. In ovarian neoplasms, BRAF, but not KRAS, mutations are restricted to low-grade serous tumours.
Sieben NL; Macropoulos P; Roemen GM; Kolkman-Uljee SM; Jan Fleuren G; Houmadi R; Diss T; Warren B; Al Adnani M; De Goeij AP; Krausz T; Flanagan AM
J Pathol; 2004 Mar; 202(3):336-40. PubMed ID: 14991899
[TBL] [Abstract][Full Text] [Related]
7. KRAS and BRAF mutations in ovarian tumors: a comprehensive study of invasive carcinomas, borderline tumors and extraovarian implants.
Mayr D; Hirschmann A; Löhrs U; Diebold J
Gynecol Oncol; 2006 Dec; 103(3):883-7. PubMed ID: 16806438
[TBL] [Abstract][Full Text] [Related]
8. Molecular Genetic Analysis of Ovarian Brenner Tumors and Associated Mucinous Epithelial Neoplasms: High Variant Concordance and Identification of Mutually Exclusive RAS Driver Mutations and MYC Amplification.
Tafe LJ; Muller KE; Ananda G; Mitchell T; Spotlow V; Patterson SE; Tsongalis GJ; Mockus SM
Am J Pathol; 2016 Mar; 186(3):671-7. PubMed ID: 26797085
[TBL] [Abstract][Full Text] [Related]
9. Flow cytometry and AgNORs in benign, borderline, and malignant mucinous and serous tumours of the ovary.
Griffiths AP; Cross D; Kingston RE; Harkin P; Wells M; Quirke P
Int J Gynecol Pathol; 1993 Oct; 12(4):307-14. PubMed ID: 8253547
[TBL] [Abstract][Full Text] [Related]
10. [Expression of topoisomerase III alpha in epithelial ovarian tumors of different types and relation between the expression of topoisomerase III alpha and the clinical pathology of tumor].
Zhang WY; Pan Y; Zhu LR; Zhang JZ; Zhang M; Feng K; Zhou L; Yu L; Zhang XM; Ng SW
Zhonghua Yi Xue Za Zhi; 2005 Nov; 85(42):2988-91. PubMed ID: 16324386
[TBL] [Abstract][Full Text] [Related]
11. [Expression and significance of p-AKT, p-GSK3β and β-catenin in epithelial carcinoma of ovary].
Wei X; Lü QJ; Sun HX; Qi YF; Wang JO; Cao CC
Zhonghua Bing Li Xue Za Zhi; 2012 Feb; 41(2):86-90. PubMed ID: 22455883
[TBL] [Abstract][Full Text] [Related]
12. [Expression and promotor methylation of p73 gene in ovarian epithelial tumors].
Zhang YL; Guo XR; Shen DH; Cheng YX; Liang XD; Chen YX; Wang Y
Zhonghua Bing Li Xue Za Zhi; 2012 Jan; 41(1):33-8. PubMed ID: 22455848
[TBL] [Abstract][Full Text] [Related]
13. Multipoint Kras oncogene mutations potentially indicate mucinous carcinoma on the entire spectrum of mucinous ovarian neoplasms.
Lee YJ; Lee MY; Ruan A; Chen CK; Liu HP; Wang CJ; Chao WR; Han CP
Oncotarget; 2016 Dec; 7(50):82097-82103. PubMed ID: 27888800
[TBL] [Abstract][Full Text] [Related]
14. Expression of REG4 in ovarian mucinous tumors.
Huang Q; Chen X; Lu W; Lai M; Lu B
Appl Immunohistochem Mol Morphol; 2014 Apr; 22(4):295-301. PubMed ID: 23958547
[TBL] [Abstract][Full Text] [Related]
15. Nuclear morphometry and AgNOR quantification: computerized image analysis on ovarian mucinous tumor imprints.
Versa-Ostojić D; Stanković T; Stemberger-Papić S; Vrdoljak-Mozetic D; Manestar M; Krasević M
Anal Quant Cytol Histol; 2008 Jun; 30(3):160-8. PubMed ID: 18630841
[TBL] [Abstract][Full Text] [Related]
16. Mutations in the KRAS gene in ovarian tumors.
Dobrzycka B; Terlikowski SJ; Kowalczuk O; Niklińska W; Chyczewski L; Kulikowski M
Folia Histochem Cytobiol; 2009; 47(2):221-4. PubMed ID: 19995707
[TBL] [Abstract][Full Text] [Related]
17. Targeted deep sequencing of mucinous ovarian tumors reveals multiple overlapping RAS-pathway activating mutations in borderline and cancerous neoplasms.
Mackenzie R; Kommoss S; Winterhoff BJ; Kipp BR; Garcia JJ; Voss J; Halling K; Karnezis A; Senz J; Yang W; Prigge ES; Reuschenbach M; Doeberitz MV; Gilks BC; Huntsman DG; Bakkum-Gamez J; McAlpine JN; Anglesio MS
BMC Cancer; 2015 May; 15():415. PubMed ID: 25986173
[TBL] [Abstract][Full Text] [Related]
18. C-myc oncogene product P62c-myc in ovarian mucinous neoplasms: immunohistochemical study correlated with malignancy.
Polacarz SV; Hey NA; Stephenson TJ; Hill AS
J Clin Pathol; 1989 Feb; 42(2):148-52. PubMed ID: 2921356
[TBL] [Abstract][Full Text] [Related]
19. [Expressions of Cx43 and Skp2 in epithelial ovarian tumor and their clinical significances].
Hu YQ; Liu YJ
Ai Zheng; 2005 Jan; 24(1):104-9. PubMed ID: 15642212
[TBL] [Abstract][Full Text] [Related]
20. [Expression of hSef and FGF-2 in epithelial ovarian tumor].
Feng QL; Shi HR; Qiao LJ; Zhao J
Zhonghua Zhong Liu Za Zhi; 2011 Oct; 33(10):770-4. PubMed ID: 22335910
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
